Two Sigma Investments
ALNY icon

Two Sigma Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Two Sigma Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,000
Closed -$1.76M – 3054
2017
Q3 		$1.76M Buy
15,000
+3,500
+30% +$299K 0.01% 1377
2017
Q2 		$917K Sell
11,500
-1,800
-14% -$115K ﹤0.01% 1950
2017
Q1 		$682K Buy
+13,300
New +$615K ﹤0.01% 2140
2016
Q4 		– Sell
-11,400
Closed -$773K – 3045
2016
Q3 		$773K Buy
+11,400
New +$804K ﹤0.01% 2152

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments's ALNY Position: Q1 2026 in Review

Two Sigma Investments increased its Alnylam Pharmaceuticals (ALNY) stake by 223% in Q1 2026, buying an estimated $468M and bringing the position to 1,992,577 shares worth $659M. The position accounts for 0.53% of the portfolio, ranked #20.

Two Sigma Investments first reported a position in ALNY in Q2 2013 and has held it in 25 quarters since. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Two Sigma Investments held 1,992,577 shares of Alnylam Pharmaceuticals worth $659M as of Q1 2026.
  • Two Sigma Investments bought 1,376,457 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $468M.
  • Alnylam Pharmaceuticals made up 0.53% of Two Sigma Investments's portfolio in Q1 2026, its #20 holding.
  • Two Sigma Investments first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 25 quarters since.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.